Applicant, as named in the Orange Book

Bausch And Lomb

Next listed expiry: Vyzulta on 21 Feb 2029. 3 products with live protection, 10 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Vyzulta latanoprostene bunod	latanoprostene bunod	207795	21 Feb 2029	patent
Besivance besifloxacin hydrochloride	besifloxacin hydrochloride	022308	9 Jan 2031	patent
Prolensa bromfenac sodium	bromfenac sodium	203168	11 Nov 2033	patent, carve-out possible

Recent events

25 Oct 2026Zylet · First generic approved 10 Dec 2025
25 Oct 2026Zylet · Generic approved 10 Dec 2025

Products without listed protection (10)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Alaway ketotifen fumarate	ketotifen fumarate	021996	open now	no listed protection
Alrex loteprednol etabonate	loteprednol etabonate	020803	open now	no listed protection
Children's Alaway ketotifen fumarate	ketotifen fumarate	021996	open now	no listed protection
Istalol timolol maleate	timolol maleate	021516	open now	no listed protection
Lotemax loteprednol etabonate	loteprednol etabonate	200738	open now	no listed protection
Lotemax loteprednol etabonate	loteprednol etabonate	020583	open now	no listed protection
Miochol-E acetylcholine chloride	acetylcholine chloride	020213	open now	no listed protection
Opcon-A naphazoline hydrochloride; pheniramine maleate	naphazoline hydrochloride; pheniramine maleate	020065	open now	no listed protection
Zirgan ganciclovir	ganciclovir	022211	open now	no listed protection
Zylet loteprednol etabonate; tobramycin	loteprednol etabonate; tobramycin	050804	open now	no listed protection